These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

335 related items for PubMed ID: 34803927

  • 1. Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside.
    Wu L, Tsang VHM, Sasson SC, Menzies AM, Carlino MS, Brown DA, Clifton-Bligh R, Gunton JE.
    Front Endocrinol (Lausanne); 2021; 12():764138. PubMed ID: 34803927
    [Abstract] [Full Text] [Related]

  • 2. Checkpoint Inhibitor-Associated Autoimmune Diabetes Is Distinct From Type 1 Diabetes.
    Tsang VHM, McGrath RT, Clifton-Bligh RJ, Scolyer RA, Jakrot V, Guminski AD, Long GV, Menzies AM.
    J Clin Endocrinol Metab; 2019 Nov 01; 104(11):5499-5506. PubMed ID: 31265074
    [Abstract] [Full Text] [Related]

  • 3. Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy.
    Wu L, Carlino MS, Brown DA, Long GV, Clifton-Bligh R, Mellor R, Moore K, Sasson SC, Menzies AM, Tsang V, Gunton JE.
    J Clin Endocrinol Metab; 2024 Apr 19; 109(5):1301-1307. PubMed ID: 37997380
    [Abstract] [Full Text] [Related]

  • 4. Pembrolizumab induced type 1 diabetes mellitus in a patient with metastatic melanoma and literature review on steroids as a treatment option.
    Greene A, Penner S, Kunesh J, Altaf A, McGrade W, Niu J.
    J Oncol Pharm Pract; 2024 Sep 19; 30(6):1084-1088. PubMed ID: 38544442
    [Abstract] [Full Text] [Related]

  • 5. Risk Factors and Characteristics of Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes.
    Wu L, Tsang V, Menzies AM, Sasson SC, Carlino MS, Brown DA, Clifton-Bligh R, Gunton JE.
    Diabetes Care; 2023 Jun 01; 46(6):1292-1299. PubMed ID: 37220262
    [Abstract] [Full Text] [Related]

  • 6. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
    Kähler KC, Kosova K, Bohne AS, Schreiber S, Hauschild A.
    Eur J Cancer; 2020 Oct 01; 138():169-171. PubMed ID: 32890812
    [No Abstract] [Full Text] [Related]

  • 7. Nivolumab-induced fulminant type 1 diabetes with precipitous fall in C-peptide level.
    Miyauchi M, Toyoda M, Zhang J, Hamada N, Yamawaki T, Tanaka J, Harada K, Kashizaki F, Fukagawa M.
    J Diabetes Investig; 2020 May 01; 11(3):748-749. PubMed ID: 31587459
    [Abstract] [Full Text] [Related]

  • 8. Recovery from insulin dependence in immune checkpoint inhibitor-associated diabetes mellitus: A case report.
    Okubo M, Hataya Y, Fujimoto K, Iwakura T, Matsuoka N.
    J Diabetes Investig; 2023 Jan 01; 14(1):147-150. PubMed ID: 36251515
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. New onset diabetes with ketoacidosis following nivolumab immunotherapy: A case report and review of literature.
    Delasos L, Bazewicz C, Sliwinska A, Lia NL, Vredenburgh J.
    J Oncol Pharm Pract; 2021 Apr 01; 27(3):716-721. PubMed ID: 32723064
    [Abstract] [Full Text] [Related]

  • 12. Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the literature.
    Ning P, Liu S, Cao H.
    J Med Case Rep; 2024 Jan 22; 18(1):51. PubMed ID: 38247005
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Immune checkpoint inhibitors-induced diabetes mellitus (review).
    Chen J, Hou X, Yang Y, Wang C, Zhou J, Miao J, Gong F, Ge F, Chen W.
    Endocrine; 2024 Nov 22; 86(2):451-458. PubMed ID: 38955861
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Diabetes mellitus secondary to treatment with immune checkpoint inhibitors.
    Venetsanaki V, Boutis A, Chrisoulidou A, Papakotoulas P.
    Curr Oncol; 2019 Feb 22; 26(1):e111-e114. PubMed ID: 30853817
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.